(CNSX:IDK),(OTC US:IDKFF),(Other OTC:IDKFF),(CNSX:IDK.CN), TORONTO, Oct. 29, 2025 (GLOBE NEWSWIRE) — ThreeD Capital Inc. (“ThreeD” or the “Company”) (CSE:IDK) (OTCQX:IDKFF), a Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, is pleased to congratulate HyperCycle on its recent announcement regarding the establishment of a $1.1 billion joint […]

(Other OTC:ETCG),(OTC US:ETCG),(OTC US:ETHE),(Other OTC:ETHE),(OTC US:ETH),(Other OTC:ETH),(NYSE Arca:GBTC),(OTC US:GDLC),(Other OTC:GDLC),(OTC US:LTCN),(Other OTC:LTCN),(OTC US:BCHG),(Other OTC:BCHG),(OTC US:ZCSH),(Other OTC:ZCSH),(OTC US:GXLM),(Other OTC:GXLM),(OTC US:HZEN),(Other OTC:HZEN),(OTC US:MANA),(Other OTC:MANA),(OTC US:GBAT),(Other OTC:GBAT),(OTC US:GLNK),(Other OTC:GLNK),(OTC US:FILG),(Other OTC:FILG),(OTC US:GLIV),(Other OTC:GLIV),(OTC US:DEFG),(Other OTC:DEFG),(OTC US:GSOL),(Other OTC:GSOL),(NYSE Arca:GDLC),(NYSE Arca:GSOL), STAMFORD, Conn., Oct. 29, 2025 (GLOBE NEWSWIRE) — Grayscale Investments(R), the world's largest digital asset-focused investment platform*, today announced

(NASDAQ:LFCR), Lifecore to Execute Commercial Site Transfer and Become New Supplier of Choice for Leading Commercial Injectable Pharmaceutical Product Represents Second Agreement Signed with Same Major Multinational Organization in Recent Months Separate Pre-Clinical Formulation Development Agreement Signed with New Early-Stage Biotech Customer CHASKA, Minn., Oct. 29, 2025 (GLOBE NEWSWIRE) — Lifecore Biomedical, Inc. (NASDAQ: LFCR)

(NASDAQ:ALMU), GOLETA, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) — Aeluma, Inc. (NASDAQ:ALMU), a semiconductor company specializing in high-performance, scalable technologies for mobile, AI, defense and aerospace, robotics, automotive, AR/VR, and quantum computing, today announced it will issue its financial results for the first quarter of fiscal 2026, which ended September 30, 2025, after the U.S.

(TSX:BLX), UASHAT, Canada, Oct. 29, 2025 (GLOBE NEWSWIRE) — Apuiat Wind Farm L.P., a 50-50 partnership between the Innu communities and Boralex Inc., is proud to announce that the Apuiat Wind Farm has reached commercial operation. The 200 MW facility is located on the Nitassinan (traditional territory) of the Uashat mak Mani-utenam First Nation. The

(Neo:VRNO.NE),(OTC US:VRNOF),(OtherOTC:VRNOF), CHICAGO, Oct. 29, 2025 (GLOBE NEWSWIRE) — Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced its financial results for the third quarter ended September 30, 2025, which were prepared in accordance with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”). Third Quarter 2025

(NASDAQ:AXGN), ALACHUA, Fla. and TAMPA, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) — Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the third quarter ended September 30, 2025. Third Quarter Financial Results Third quarter revenue

(NASDAQ:AMRN), Company completes transition to fully partnered commercialization model across all international markets Q3 2025 performance reflects initial impact of new approach to Europe, ongoing expansion of Rest-of-World demand, continued success in managing US market, and initial operating margin improvements following corporate rightsizing Targeting sustainable positive free cash flow in 2026 DUBLIN and BRIDGEWATER, N.J.,

New York, NY, Oct. 29, 2025 (GLOBE NEWSWIRE) — Ultravox, the real-time Voice AI platform, today announced the launch of production-ready global calling for AI voice agents, powered by Voximplant, a leading cloud communications platform. Developers can now connect their voice AI agents to existing phone systems – without the need for complex telecom setup

(NasdaqGM:FULC), ― Announced encouraging results in July 2025 from the 12 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― Enrollment complete in the 20 mg dose cohort (n=12) of the PIONEER trial; on track to provide data from the 20 mg dose cohort by year-end